NAMS NewAmsterdam Pharma
- 20.200
- +0.080+0.40%
- 20.200
- 0.0000.00%
NewAmsterdam Pharma News
RBC Capital Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $31
RBC Capital Sticks to Their Buy Rating for NewAmsterdam Pharma Company (NAMS)
Scotiabank Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $35
NewAmsterdam Pharma Analyst Ratings
Needham Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $36
Buy Rating for NewAmsterdam Pharma Amid Promising TANDEM Trial Results and Upcoming BROADWAY Trial Expectations
Jefferies Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $45
Scotiabank Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $35
Piper Sandler Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $37
TD Cowen Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating
NewAmsterdam Pharma Company (NAMS) Receives a Buy From Piper Sandler
Needham Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $36
Leerink Partners Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $42
Scotiabank Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $35
RBC Capital Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $31
NewAmsterdam Pharma Analyst Ratings
NewAmsterdam Pharma's Strategic Advancements: Phase 3 Trials and Buy Rating Insight
Needham Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $36
TD Cowen Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating
Piper Sandler Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $37
Analysis
Price Target
No Data
No Data